 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Daniel Pollyea and Andrew Kent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.768 |
|
|
|
-
Kent A, Pollyea DA. Top advances of the year: Leukemia. Cancer. 2023 04 01; 129(7):981-985.
Score: 0.821
-
Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, Pollyea DA. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020 07 14; 4(13):3102-3108.
Score: 0.692
-
Gilbert JS, Connor M, Bosma G, Zhang J, McMahon CM, Amaya ML, Gutman J, Schwartz M, Kent A, Abbott D, Pollyea DA. Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis. Am J Hematol. 2025 Nov; 100(11):2140-2143.
Score: 0.246
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11.
Score: 0.230
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
Score: 0.216
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
Score: 0.210
-
Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M. Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia. Haematologica. 2025 Sep 11.
Score: 0.062
-
O'Brien C, Nursimulu N, Tyagi A, Culp-Hill R, Arruda A, Murphy T, Minden MD, Kent A, Stevens BM, Pollyea DA, Hope K, Kumar S, Reisz JA, D'Alessandro A, Jones CL. Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia. Blood. 2025 Aug 26.
Score: 0.062
-
Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, Rose A, Hayden A, Siddon A, Lykon J, Madarang E, Swoboda DM, Padron E, Sweet K, Sallman DA, Lancet J, Carraway HE, Watts J, Zeidan A, Pollyea DA, Komrokji RS. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (=?70?Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. Am J Hematol. 2025 Oct; 100(10):1920-1923.
Score: 0.061
-
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon CM, Gutman J, Pollyea DA, Amaya ML. Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. Leuk Lymphoma. 2025 Mar 13; 1-3.
Score: 0.060
-
Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, Pollyea DA, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024 Dec; 65(14):2228-2230.
Score: 0.058
-
Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022 07 12; 6(13):3879-3883.
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|